CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
Completed · Phase 3
Conditions studied: Primary Immunodeficiency
In brief
Summary for SCGAM-03: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (Octanorm) in patients with primary immunodeficiency diseases who have completed the SCGAM-01 trial. Summary for SCGAM-03 in Canada: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases, including (but not limited to) those who have completed the SCGAM-01 trial
Key facts
- Study ID
- NCT03907241
- Run by
- Octapharma
- People needed
- 27
- Starts
- 2016-03-01
- Expected to finish
- 2019-09-05
- Last updated by the study team
- 2020-10-27
Who can join
Age: 2 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Octapharma Research Site — Irvine, California, United States
- Octapharma Research Site — San Diego, California, United States
- Octapharma Research Site — Centennial, Colorado, United States
- Octapharma Research Site — Papillion, Nebraska, United States
- Octapharma Research Site — Toledo, Ohio, United States
- Octapharma Research Site — Frisco, Texas, United States
- Octapharma Research Site — Edmonton, Alberta, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.